First Horizon Advisors Inc. Increases Stock Position in Stryker Co. (NYSE:SYK)

First Horizon Advisors Inc. raised its holdings in shares of Stryker Co. (NYSE:SYK) by 2.9% during the fourth quarter, Holdings Channel reports. The fund owned 2,146 shares of the medical technology company’s stock after buying an additional 61 shares during the period. First Horizon Advisors Inc.’s holdings in Stryker were worth $773,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Pinnacle Financial Partners Inc grew its position in Stryker by 1.3% during the fourth quarter. Pinnacle Financial Partners Inc now owns 6,795 shares of the medical technology company’s stock valued at $2,447,000 after acquiring an additional 84 shares during the last quarter. Callan Capital LLC grew its position in Stryker by 6.1% during the fourth quarter. Callan Capital LLC now owns 701 shares of the medical technology company’s stock valued at $252,000 after acquiring an additional 40 shares during the last quarter. Dividend Assets Capital LLC grew its position in Stryker by 4.0% during the fourth quarter. Dividend Assets Capital LLC now owns 29,093 shares of the medical technology company’s stock valued at $10,475,000 after acquiring an additional 1,124 shares during the last quarter. Transcend Capital Advisors LLC grew its position in Stryker by 11.5% during the fourth quarter. Transcend Capital Advisors LLC now owns 10,942 shares of the medical technology company’s stock valued at $3,940,000 after acquiring an additional 1,132 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT grew its position in Stryker by 2.9% during the fourth quarter. Bradley Foster & Sargent Inc. CT now owns 60,329 shares of the medical technology company’s stock valued at $21,721,000 after acquiring an additional 1,679 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

Shares of Stryker stock opened at $388.11 on Tuesday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm has a market capitalization of $148.09 billion, a P/E ratio of 50.01, a P/E/G ratio of 2.93 and a beta of 0.96. The business has a fifty day simple moving average of $378.38 and a two-hundred day simple moving average of $369.78. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the company earned $3.46 earnings per share. On average, equities analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

Analysts Set New Price Targets

A number of research analysts have commented on SYK shares. Evercore ISI increased their price target on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Truist Financial raised their target price on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Canaccord Genuity Group raised their target price on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Robert W. Baird raised their target price on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, BTIG Research raised their target price on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $422.15.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.